


## LEGEND-T2DM Evidence Dissemination Summary

Target: **exenatide**, Comparator: **canagliflozin** Outcome: **Joint pain**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	38,725	21,766	144	6.62
Merative CCAE	3,273	1,839	29	15.77
Merative MDCCD	597	297	8	26.93
Merative MDCR	242	110	<5	<45.43
Optum Clinformatics	1,862	1,166	32	27.45
Optum EHR	3,375	1,379	24	17.41
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

